Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

CBD shows promise for schizophrenia in new trial

NCT ID NCT02926859

Disease control Sponsor: Central Institute of Mental Health, Mannheim Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase II trial tests whether cannabidiol (CBD) capsules, added to standard antipsychotic medication, can help people with early schizophrenia recover better and stay on treatment longer. 180 participants receive either CBD or placebo for 26 weeks. The goal is to see if CBD improves symptoms and reduces side effects like weight gain and movement problems.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
cannabidiol (CBD) capsules
What this could lead to
If successful, this could point toward a safer, better-tolerated add-on treatment for schizophrenia that helps patients stay on therapy longer.
What could go wrong
This is a mid-stage trial with 180 participants, so results may not apply to all patients. CBD may not outperform placebo, and long-term safety is still unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 180 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2017

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Informed consent given by the subject * DSM-IV-TR diagnosis of schizophrenic psychosis (295.10-30, 295.90) * First documented diagnosis of schizophrenia must not be no older than seven years. * Patients must receive a stable dose of amisulpride, aripiprazole, olanzapine, quetiapine or risperidone (TAU: treatment as usual) at least 4 weeks prior to inclusion in the study to ensure that the maximal effect of the previous medication has been received. * Initial PANSS total score of ≤ 75 at baseline. * proper contraception in female patients of childbearing potential * body mass index between 18 and 40. Exclusion Criteria: * Lack of accountability * positive urine drug-screening for illicit drugs at screening (except cannabinoids and benzodiazepines) * serious suicidal risk at screening visit * other relevant interferences of axis 1 according to diagnostic evaluation (MINI) including residual forms of schizophrenia. * other relevant neurological or other medical disorders * pregnancy or lactation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Schizophrenia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

schizophrenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Schizophrenia

Contacts and locations

Locations

  • Dep. of Psychiatry and Psychotherapy, Central Institute of Mental Health

    Mannheim, Baden-Wurttemberg, 68159, Germany

  • Department of Psychiatry und Psychotherapy, University Hospital Hamburg-Eppendorf

    Hamburg, 20246, Germany

  • Department of Psychiatry, Psychotherapy, and Psychosomatics, RWTH Aachen

    Aachen, North Rhine-Westphalia, 52074, Germany

  • Dept. of Psychiatry and Psychotherapy, Charité, Campus Charité-Mitte

    Berlin, B, 10117, Germany

  • Dept. of Psychiatry and Psychotherapy, Ludwig-Maximillians-University Munich

    Munich, Bavaria, 80336, Germany

  • Dept. of Psychiatry and Psychotherapy, University Hospital of Cologne

    Cologne, North Rhine-Westphalia, 50924, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.